Shanghai Helioson Pharmaceutical Co. Ltd. has patented molecular glue degraders comprising cereblon (CRBN) binding agents acting as proto-oncogene Vav (VAV1) degradation inducers found to be potentially useful for the treatment of autoimmune disease and cancer.
Shenzhen Salubris Pharmaceuticals Co. Ltd. has synthesized relaxin family peptide receptor 1 (RXFP1) receptor agonists reported to be potentially useful for the treatment of heart failure.
Shanghai Qingrun Pharmaceutical Technology Co. Ltd. has disclosed new S-adenosylmethionine synthase isoform type-2 (Mat2A) inhibitors that are potentially useful for the treatment of cancer.
Innovo Therapeutics Inc. has divulged sulfonamide derivatives acting as N-myristoyltransferase 1 (NMT1) inhibitors found to be potentially useful for the treatment of cancer, protozoal and viral infection.
Leto Laboratories Co. Ltd. has identified macro cyclic peptides acting as calcitonin receptor (CALCR; CT-R) and amylin dual receptor agonists reported to be potentially useful for the treatment of atherosclerosis, type 1 diabetes, dyspepsia, myocardial infarction, obesity and more.
Jiangsu Nhwa Pharmaceutical Co. Ltd. has disclosed κ-opioid receptor antagonists that are potentially useful for the treatment of neurological disorders.
Shenzhen Chipscreen Biosciences Co. Ltd. has divulged histone deacetylase (HDAC) inhibitors found to be potentially useful for the treatment of cancer.
Shanghai Curegene Pharmaceutical Co. Ltd. has identified thyroid hormone receptor β (THR-β) agonists that are potentially useful for the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD; NAFLD), diabetes and obesity.
Scientists from the Purdue Research Foundation have prepared and tested prostate-specific membrane antigen (PSMA)-targeting ligands covalently linked to the poly(ADP-ribose) polymerase (PARP) inhibitor niraparib through a releasable, reductively cleavable NADS linker.
RSS